Qingcheng New Drug-B (02396.HK) intends to apply for full circulation of H-shares.

Zhitong Finance APP reported that Qingcheng New Drug-B (02396.HK) announced that, in light of the "Guidelines," the Board of Directors has reviewed and approved the conversion of domestic shares held by shareholders into H-shares (H-shares) and the listing and circulation of such H-shares on the main board of the Stock Exchange (full circulation of H-shares). After obtaining all relevant approvals (including the filing notice from the China Securities Regulatory Commission and the approval from the Stock Exchange) and complying with all applicable laws, rules, and regulations, 21,681,762 domestic shares will be converted into H-shares, and the company will apply to the Stock Exchange for the listing and trading of such H-shares on the main board.